Nanobiotix S.A. (NASDAQ:NBTX – Free Report) – Research analysts at Leerink Partnrs raised their FY2024 EPS estimates for Nanobiotix in a research note issued on Tuesday, March 18th. Leerink Partnrs analyst J. Chang now anticipates that the company will post earnings per share of ($0.94) for the year, up from their previous estimate of ($1.22). The consensus estimate for Nanobiotix’s current full-year earnings is ($1.18) per share. Leerink Partnrs also issued estimates for Nanobiotix’s FY2025 earnings at ($0.51) EPS and FY2026 earnings at $0.84 EPS.
Separately, UBS Group upgraded shares of Nanobiotix to a “hold” rating in a research report on Monday, February 17th.
Nanobiotix Trading Down 2.0 %
NASDAQ NBTX opened at $3.73 on Friday. Nanobiotix has a 12 month low of $2.76 and a 12 month high of $7.51. The company’s 50 day simple moving average is $3.49 and its 200 day simple moving average is $3.93.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the business. OLD Mission Capital LLC acquired a new position in Nanobiotix in the fourth quarter worth approximately $139,000. Jane Street Group LLC acquired a new position in Nanobiotix in the 4th quarter worth approximately $73,000. Millennium Management LLC acquired a new position in Nanobiotix in the 4th quarter worth approximately $39,000. Finally, Geode Capital Management LLC acquired a new position in Nanobiotix in the 4th quarter worth approximately $29,000. Institutional investors and hedge funds own 38.81% of the company’s stock.
About Nanobiotix
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Read More
- Five stocks we like better than Nanobiotix
- How to Invest in the FAANG Stocks
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- What is a Stock Market Index and How Do You Use Them?
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
- How to Profit From Value Investing
- Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
